These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

406 related articles for article (PubMed ID: 25402569)

  • 1. Diffuse high intensity PD-L1 staining in thymic epithelial tumors.
    Padda SK; Riess JW; Schwartz EJ; Tian L; Kohrt HE; Neal JW; West RB; Wakelee HA
    J Thorac Oncol; 2015 Mar; 10(3):500-8. PubMed ID: 25402569
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of a panel of druggable gene mutations and of ALK and PD-L1 expression in a series of thymic epithelial tumors (TETs).
    Tiseo M; Damato A; Longo L; Barbieri F; Bertolini F; Stefani A; Migaldi M; Gnetti L; Camisa R; Bordi P; Buti S; Rossi G
    Lung Cancer; 2017 Feb; 104():24-30. PubMed ID: 28212996
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunohistochemical status of PD-L1 in thymoma and thymic carcinoma.
    Katsuya Y; Fujita Y; Horinouchi H; Ohe Y; Watanabe S; Tsuta K
    Lung Cancer; 2015 May; 88(2):154-9. PubMed ID: 25799277
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of PD-L1 and other immunotherapeutic targets in thymic epithelial tumors.
    Arbour KC; Naidoo J; Steele KE; Ni A; Moreira AL; Rekhtman N; Robbins PB; Karakunnel J; Rimner A; Huang J; Riely GJ; Hellmann MD
    PLoS One; 2017; 12(8):e0182665. PubMed ID: 28771603
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HSP27 and 70 expression in thymic epithelial tumors and benign thymic alterations: diagnostic, prognostic and physiologic implications.
    Janik S; Schiefer AI; Bekos C; Hacker P; Haider T; Moser J; Klepetko W; Müllauer L; Ankersmit HJ; Moser B
    Sci Rep; 2016 Apr; 6():24267. PubMed ID: 27097982
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Programmed Death-ligand 1 (PD-L1) Expression in Thymic Epithelial Tumors.
    Bedekovics J; Beke L; Mokanszki A; Szilagyi S; Mehes G
    Appl Immunohistochem Mol Morphol; 2020 Jan; 28(1):1-9. PubMed ID: 30499814
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression Patterns, Prognostic Value, and Intratumoral Heterogeneity of PD-L1 and PD-1 in Thymoma and Thymic Carcinoma.
    Owen D; Chu B; Lehman AM; Annamalai L; Yearley JH; Shilo K; Otterson GA
    J Thorac Oncol; 2018 Aug; 13(8):1204-1212. PubMed ID: 29702286
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Programmed death ligand-1 expression is associated with poor disease free survival in salivary gland carcinomas.
    Mukaigawa T; Hayashi R; Hashimoto K; Ugumori T; Hato N; Fujii S
    J Surg Oncol; 2016 Jul; 114(1):36-43. PubMed ID: 27111278
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of programmed death 1 (PD-1) and its ligand (PD-L1) in thymic epithelial tumors: Impact on treatment efficacy and alteration in expression after chemotherapy.
    Katsuya Y; Horinouchi H; Asao T; Kitahara S; Goto Y; Kanda S; Fujiwara Y; Nokihara H; Yamamoto N; Watanabe S; Tsuta K; Ohe Y
    Lung Cancer; 2016 Sep; 99():4-10. PubMed ID: 27565906
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic and clinicopathological roles of programmed death-ligand 1 (PD-L1) expression in thymic epithelial tumors: A meta-analysis.
    Koh HM; Jang BG; Lee HJ; Hyun CL
    Thorac Cancer; 2020 Nov; 11(11):3086-3098. PubMed ID: 32926538
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PD-1 and PD-L1 expression in thymic epithelial tumours and non-neoplastic thymus.
    Bagir EK; Acikalin A; Avci A; Gumurdulu D; Paydas S
    J Clin Pathol; 2018 Jul; 71(7):637-641. PubMed ID: 29439008
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of programmed cell death-ligand 1 and its correlation with clinical outcomes in gliomas.
    Zeng J; Zhang XK; Chen HD; Zhong ZH; Wu QL; Lin SX
    Oncotarget; 2016 Feb; 7(8):8944-55. PubMed ID: 26771840
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinicopathologic and Prognostic Implications of Programmed Death Ligand 1 Expression in Thymoma.
    Yokoyama S; Miyoshi H; Nishi T; Hashiguchi T; Mitsuoka M; Takamori S; Akagi Y; Kakuma T; Ohshima K
    Ann Thorac Surg; 2016 Apr; 101(4):1361-9. PubMed ID: 26794891
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PD-L1, PD-1, CD4, and CD8 expression in neoplastic and nonneoplastic thymus.
    Marchevsky AM; Walts AE
    Hum Pathol; 2017 Feb; 60():16-23. PubMed ID: 27746267
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of PD-L1, transforming growth factor-β expression and tumor-infiltrating CD8
    Duan J; Liu X; Chen H; Sun Y; Liu Y; Bai H; Wang J
    Thorac Cancer; 2018 Nov; 9(11):1341-1353. PubMed ID: 30168897
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thymic epithelial tumors express vascular endothelial growth factors and their receptors as potential targets of antiangiogenic therapy: a tissue micro array-based multicenter study.
    Lattanzio R; La Sorda R; Facciolo F; Sioletic S; Lauriola L; Martucci R; Gallo E; Palmieri G; Evoli A; Alessandrini G; Ruco L; Rendina EA; Truini M; Chiarle R; Barreca A; Pich A; Ascani S; Remotti D; Tunesi G; Granone P; Ratto GB; Puma F; Pescarmona E; Piantelli M; Marino M; ; Carlini S; Cerasoli V; Corzani F; Melis E; Filippetti M; Canalini P; Palestro G; Lalle M; Ruffini E; Ceribelli A; Rinaldi M
    Lung Cancer; 2014 Aug; 85(2):191-6. PubMed ID: 24908332
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Arginase Pathway Markers of Immune-Microenvironment in Thymic Epithelial Tumors and Small Cell Lung Cancer.
    Umemura S; Chen V; Chahine JJ; Kallakury B; Zhao X; Lee H; Avantaggiati ML; He Y; Wang C; Giaccone G
    Clin Lung Cancer; 2022 Mar; 23(2):e140-e147. PubMed ID: 34393062
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elevated CRP levels predict poor outcome and tumor recurrence in patients with thymic epithelial tumors: A pro- and retrospective analysis.
    Janik S; Bekos C; Hacker P; Raunegger T; Ghanim B; Einwallner E; Beer L; Klepetko W; Müllauer L; Ankersmit HJ; Moser B
    Oncotarget; 2017 Jul; 8(29):47090-47102. PubMed ID: 28514756
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of PD-1 and PD-L1 in thymic epithelial neoplasms.
    Weissferdt A; Fujimoto J; Kalhor N; Rodriguez J; Bassett R; Wistuba II; Moran CA
    Mod Pathol; 2017 Jun; 30(6):826-833. PubMed ID: 28281549
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinicopathologic Significance and Immunogenomic Analysis of Programmed Death-Ligand 1 (PD-L1) and Programmed Death 1 (PD-1) Expression in Thymic Epithelial Tumors.
    Song JS; Kim D; Kwon JH; Kim HR; Choi CM; Jang SJ
    Front Oncol; 2019; 9():1055. PubMed ID: 31681591
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 21.